Cardiovascular Safety and Benefits of Noninsulin Antihyperglycemic Drugs for the Treatment of Type 2 Diabetes Mellitus-Part 1.

摘要: Cardiovascular disease (CVD) is a major contributor to the morbidity and mortality associated with type 2 diabetes mellitus (T2DM). With T2DM growing in pandemic proportions, there will be profound healthcare implications of CVD person diabetes. The ideal drugs improve outcomes are those having antiglycemic efficacy addition cardiovascular (CV) safety, which has determined appropriately designed CV outcome trials as mandated by regulatory agencies. Available evidence largely supportive metformin's safety potential risk reduction effects, whereas sulfonylureas either neutral or variable risk. Pioglitazone was also improved patients more recent antihyperglycemic medications have shown promise regards at high Glucagon-like peptide-1 receptor agonists, incretin-based therapy, were better patients, leading Food Drug Administration approval liraglutide reduce high-risk patients. Ongoing planned randomized controlled newer should clarify possibility class benefits low-moderate While metformin remains first-line therapy T2DM, glucagon-like agonists prescribed baseline outcomes. Dipeptidyl peptidase-4 inhibitors sodium-glucose cotransporter-2 discussed second part this review.